title: Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model.
abstract: OBJECTIVE
  With intraperitoneal N-methyl-D-aspartate (NMDA; 15-200 mg/kg) administration, we attempted to develop an animal model of age-specific West syndrome to serve for testing of putative anticonvulsant drugs and to determine the mechanisms of this disorder.
  
  
  METHODS
  Experiments were performed in 12-, 18-, and 60-day-old (adult) rats. The effects of systemic pretreatment with hydrocortisone (5-25 mg/kg), pyridoxine (20-250 mg/kg), and sodium valproate (VPA; 200 and 400 mg/kg) against the NMDA-induced automatisms, emprosthotonic (hyperflexion), and clonic-tonic seizures were determined. NMDA-induced EEG changes and alterations of the performance in horizontal bar, rotorod, open field, and elevated plus-maze tests were recorded.
  
  
  RESULTS
  In young rats, hydrocortisone had proconvulsant effects. High doses of pyridoxine induced epileptiform activity independent of and distinct from that induced by NMDA. Only VPA had moderate effects against the NMDA-induced syndrome. EEG consisted of periods of suppression mixed with ictal activity of serrated waves and high-voltage chaotic EEG activity. In adult rats, EEG alterations involved spike and spike-and-wave activity. NMDA also deteriorated performance of young rats in the open field, rotorod, and elevated plus maze tests.
  
  
  CONCLUSIONS
  NMDA syndrome in rats fulfills some, but not all, criteria of the West syndrome model, such as occurrence of flexion seizures, nonspecific diffuse EEG changes, refractoriness to antiepileptic therapy (but a response to VPA), as well as long-term alteration of behavioral tasks. However, NMDA-induced seizures represent an acute model without the occurrence of spontaneous seizures, whereas in the clinical situation, both the seizures and neurologic deterioration are chronic. Further, in the West syndrome and the NMDA seizure model, there is an incongruent response to therapy with antiepileptic drugs.
authors.affiliation: Department of Pathological Physiology, Third Faculty of Medicine, Charles University, Praha, Czech Republic.
authors.forename: R
authors.initials: R
authors.lastname: Kábová
authors.forename: S
authors.initials: S
authors.lastname: Liptáková
authors.forename: R
authors.initials: R
authors.lastname: Slamberová
authors.forename: M
authors.initials: M
authors.lastname: Pometlová
authors.forename: L
authors.initials: L
authors.lastname: Velísek
mesh_terms: D000367:Age Factors; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004195:Disease Models, Animal; D004569:Electroencephalography / Q000187:drug effects / Q000706:statistics & numerical data; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology / Q000627:therapeutic use; D016202:N-Methylaspartate / Q000494:pharmacology; D011736:Pyridoxine / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D012640:Seizures / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D013036:Spasms, Infantile / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D014635:Valproic Acid / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D014635:Valproic Acid; D016202:N-Methylaspartate; D011736:Pyridoxine; D006854:Hydrocortisone